Intelligence Feed event · Policy · 2026-09-12

    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy

    Question

    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy

    Direct answer

    The FDA has approved Scholar Rock's Isembyld (apitegromab-mstn), marking the first muscle-targeted therapeutic entry for spinal muscular atrophy (SMA). The treatment is designed for co-administration with current standard-of-care SMN therapies, following positive Phase 3 SAPPHIRE trial results documenting motor function improvements.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/fda-approves-scholar-rock-s-isembyld-for-spinal-muscular-atrophy-e55ac1

    POLICY
    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    The FDA has approved Scholar Rock's Isembyld (apitegromab-mstn), marking the first muscle-targeted therapeutic entry for spinal muscular atrophy (SMA). The treatment is designed for co-administration with current standard-of-care SMN therapies, following positive Phase 3 SAPPHIRE trial results documenting motor function improvements.
    SRRK
    Impact
    73
    SEP 12
    SIG
    92%
    SRRK
    FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    The FDA has approved Scholar Rock's Isembyld (apitegromab-mstn), marking the first muscle-targeted therapeutic entry for spinal muscular atrophy (SMA). The treatment is designed for co-administration with current standard-of-care SMN therapies, following positive Phase 3 SAPPHIRE trial results documenting motor function improvements.
    → Regulatory commercial authorization allows SRRK to begin product monetization in the spinal muscular atrophy market.
    Impact
    The FDA has approved Scholar Rock's Isembyld (apitegromab-mstn), marking the first muscle-targeted therapeutic entry for spinal muscular atrophy (SMA). The treatment is designed for co-administration with current standard-of-care SMN therapies, following positive Phase 3 SAPPHIRE trial results documenting motor function improvements.
    Affected
    SRRK
    Transmission
    Regulatory commercial authorization allows SRRK to begin product monetization in the spinal muscular atrophy market.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    SRRKcommercial drug approval and market launchUp1-5dThe FDA has approved Isembyld (apitegromab-mstn) for spinal muscular atrophy.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month